Get started
Author

Baohui Han

Observed names: B. Han, Bao-hui Han, Baohui HAN, Han B
ORCID: 0000-0002-6251-3771
Observed ORCID: 0000-0002-6251-3771
OpenAlex ID: A5100657202
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 · Tony S. Mok, Yi-Long Wu, et al. · New England Journal of Medicine · 8,261
PDF
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
2015 · Y.-L. Wu, C. Zhou, et al. · Annals of Oncology · 738
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
2022 · Zhijie Wang, Lin Wu, et al. · Journal of Clinical Oncology · 181
PDF
Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China
2012 · Yi‐Long WU, Da‐Tong CHU, et al. · Asia-Pacific Journal of Clinical Oncology · 47
Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells
2015 · Xueyan Zhang, Yuqing Lou, et al. · Medical Oncology · 37
A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting
2014 · Xiao-fei Wang, Yun Feng, et al. · Scientific Reports · 30
PDF
Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells
2017 · Xueyan Zhang, Yanwei Zhang, et al. · Journal of Cancer · 23
PDF
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study
2019 · Yi-Long Wu, Caicun Zhou, et al. · Lung Cancer · 16
[Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011 version)].
2012 · Xiuyi Zhi, Yilong Wu, et al. · PubMed · 15
OCT4&SOX2‐specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem‐like cells in vitro and treating drug‐resistant lung cancer mice in vivo
2018 · Xueyan Zhang, Fang Hu, et al. · Journal of Cellular Physiology · 13
Noscapine derivative 428 suppresses ferroptosis through targeting GPX4
2025 · Youping Zhang, Haoliang Shi, et al. · Redox Biology · 8
Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study
2025 · Baohui Han, Jie Liu, et al. · Journal of Thoracic Oncology · 3
P2.03-22 OCT4andSOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC And Treating Drug-Resistant Lung Cancer Mice
2018 · X. Zhang, F. Hu, et al. · Journal of Thoracic Oncology · 1
PDF
Noscapine Derivative 428 Suppresses Ferroptosis Through Targeting Gpx4
2025 · ying-li wu, ying-li wu, et al. · SSRN Electronic Journal
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
2024 · Zhijie Wang, Lin Wu, et al. · Future Oncology
PDF
1358P Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
2024 · T.M. Feinstein, B. Han, et al. · Annals of Oncology
PDF
Supplementary Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
2023 · Qing Zhou, Lin Wu, et al.
Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
2023 · Qing Zhou, Lin Wu, et al.
Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
2023 · Qing Zhou, Lin Wu, et al.
Supplementary Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
2023 · Qing Zhou, Lin Wu, et al.
The Association Between PNPLA2 Methylation in Peripheral Blood and Early-Stage Lung Cancer in a Case–Control Study
2021 · Qiao R, Li M, et al. · Dove Medical Press (Taylor and Francis Group)
PDF
P2.03-37 The Efficiency of Octamer-4 Specific Cytotoxic T Cells Induce By CD40-B Cells in Killing Lung Cancer Stem-Like Cells
2018 · X. Zhang, J. Xu, et al. · Journal of Thoracic Oncology
PDF
RAD18多型は非小細胞肺癌の中国人患者における白金ベース化学療法毒性と関連する【Powered by NICT】
2016 · Chu Tianqing, Rong Li, et al. · Acta Pharmacologica Sinica
Application of anti-angiogenesis therapy for non-small cell lung cancer
2011 · Baohui Han · World Clinical Drugs
Immunotherapy, phase I study of immunotherapy with carcinoembryonic antigen peptide -pulsed, autologous human cultured dendritic cells in patients with advanced non-small cell lung cancer
2006 · B. Han, Z. Huan, et al. · Journal of Clinical Oncology
Works count: 25
Citation count: 9,372
H-index: 10
I10-index: 10
Year
Topic
Type